High-Dose Rifampin, SQ109 and Moxifloxacin for Treating TB: The PanACEA MAMS-TB Trial
Background: Shorter regimens are urgently needed for the treatment of TB. The PanACEA MAMS-TB trial was conducted to evaluate whether 12-week combinations of high-dose rifampin, SQ109 and moxifloxacin with standard drugs reduced time to culture conversion on liquid media sufficiently to select for a phase III treatment-shortening trial. Methods: Adult patients with drug-sensitive smear-positive TB…